12-week chronic study GLP-1-H24-4 (the "Study") underway in Australia. Lexaria has completed its submission to the human research ethics committee ("HREC") for its planned addition of Study Arm 5 ...

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk ... Novo stopped a phase 3b trial of semaglutide, the active ingredient in Ozempic, early for efficacy in October 2023 and ...

Eden is providing access to a new way for individuals to explore GLP-1 therapy: a compounded semaglutide gummy, available ...

Katz, M.D., of the John A. Moran Eye Center at University of Utah Health, saw a patient who experienced sudden painless vision loss after starting semaglutide. The patient stopped using the drug ...

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.

Can GLP-1 Meds Harm Your Eyes ... who were taking GLP-1s such as semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound). Seven of the nine patients developed a condition known as ...

At least nine patients using the glucagon-like peptide 1 (GLP-1 ... patients (mean age, 57.4 years; 56% women) who developed ophthalmic complications while using semaglutide (n = 6) or tirzepatide ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that was originally ... compared to other antidiabetic drugs. 4 These observations were based on 100 million patient records ...